# Biocon

生物类似药 + 本地建设 — EMA 批准印度 mAbs 工厂.

Source: https://cn.bioecon.ru/companies/biocon/
Updated: 2026-06-24

- 国家: India

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 通过合格机构配售（QIP）募集股本印度卢比415亿（约$4.6亿），于2026年1月完成 | https://www.bioconbiologics.com/biocon-limited-concludes-rs-4150-crore-usd-460-million-equity-fundraise-through-a-%C7%ABualified-institutions-placement-%C7%ABip/ |
| 生产基地 | 印度班加罗尔Biocon Park的350,000平方英尺单抗原液（B3）设施 | https://www.biocon.com/businesses/biosimilars/global-scale-manufacturing/, https://www.bioprocessintl.com/facilities-capacity/biocon-expanded-plant-approved-to-make-avastin-biosimilar |
| 产能 | 班加罗尔单抗设施42,000升产能 | https://www.bioprocessintl.com/facilities-capacity/biocon-expanded-plant-approved-to-make-avastin-biosimilar |
| 监管批准 | EMA批准在班加罗尔单抗基地生产贝伐珠单抗与曲妥珠单抗生物类似药 | https://www.biocon.com/ema-approves-biocon-biologics-new-mabs-facility-in-india-and-renews-gmp-certifications-for-india-and-malaysia-sites/, https://www.bioprocessintl.com/facilities-capacity/biocon-expanded-plant-approved-to-make-avastin-biosimilar, https://www.prnewswire.com/news-releases/ema-approves-biocon-biologics-new-mabs-facility-in-india-and-renews-gmp-certifications-for-india-and-malaysia-sites-302180507.html |
| 认证 | 由HPRA代表EMA为班加罗尔与马来西亚基地续发的GMP符合性证书（截至2024年6月） | https://www.biocon.com/ema-approves-biocon-biologics-new-mabs-facility-in-india-and-renews-gmp-certifications-for-india-and-malaysia-sites/, https://www.bioprocessintl.com/facilities-capacity/biocon-expanded-plant-approved-to-make-avastin-biosimilar, https://www.prnewswire.com/news-releases/ema-approves-biocon-biologics-new-mabs-facility-in-india-and-renews-gmp-certifications-for-india-and-malaysia-sites-302180507.html |
| 员工人数 | 18,200余名员工（Biocon集团，截至FY2025） | https://www.biocon.com/docs/Biocon_Group_Corporate_Presentation.pdf |
| 营收 | Biocon Limited收入：$19亿；Biocon Biologics收入：$11亿（FY2025） | https://www.biocon.com/docs/Biocon_Group_Corporate_Presentation.pdf, https://www.biocon.com/docs/IR-Presentation-February-2026-no-coverletter.pdf |

独立来源: bioprocessintl.com, prnewswire.com

## 技术

- [生物制药与生物医药](https://cn.bioecon.ru/technology/biopharmaceuticals-biomedicines/)
- [面向市场准入的本地化生产](https://cn.bioecon.ru/technology/local-manufacturing-for-market-access/)